Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Retrophin Inc (RTRX)

Retrophin Inc (RTRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Retrophin Inc 3721 VALLEY CENTRE DR. SUITE 200 SAN DIEGO CA 92130 USA

www.retrophin.com P: 888-969-7879

Description:

Retrophin is a pharmaceutical company focused on the development, acquisition and commercialization of drugs for the treatment of serious, catastrophic or rare diseases for which there are currently no viable options for patients. The Company's approved products include Chenodal', Cholbam, and Thiola', and its pipeline includes compounds for several catastrophic diseases, including focal segmental glomerulosclerosis, pantothenate kinase-associated neurodegeneration, infantile spasms, nephrotic syndrome and others. Retrophin, Inc. is based in San Diego.

Key Statistics

Overview:

Market Capitalization, $K 1,238,011
Shares Outstanding, K 51,052
Annual Sales, $ 175,340 K
Annual Net Income, $ -146,430 K
Last Quarter Sales, $ 51,140 K
Last Quarter Net Income, $ -22,550 K
60-Month Beta 0.71
% of Insider Shareholders 4.63%
% of Institutional Shareholders 93.41%
Float, K 48,688
% Float 95.37%

Growth:

1-Year Return 86.32%
3-Year Return 13.05%
5-Year Return 9.28%
5-Year Revenue Growth 521.77%
5-Year Earnings Growth -51.75%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.26 on 02/24/20
Latest Earnings Date 11/05/20
Earnings Per Share ttm -1.70
EPS Growth vs. Prev Qtr 24.14%
EPS Growth vs. Prev Year 48.24%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

RTRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -29.27%
Return-on-Assets % -12.25%
Profit Margin % -83.51%
Debt/Equity 0.71
Price/Sales 7.09
Price/Cash Flow N/A
Price/Book 4.10
Book Value/Share 5.92
Interest Coverage -6.78
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar